[Update on inflammatory bowel diseases].
Watanabe
Mamoru
M
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D000069285:Infliximab; D007413:Intestinal Mucosa / Q000276:immunology; D047908:Intracellular Signaling Peptides and Proteins / Q000235:genetics; D053473:Nod2 Signaling Adaptor Protein; D011110:Polymorphism, Genetic; D019936:Probiotics / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D047908:Intracellular Signaling Peptides and Proteins; C429018:NOD2 protein, human; D053473:Nod2 Signaling Adaptor Protein; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab